{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:16:13Z","timestamp":1793232973441,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.phrs.2025.107664","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:05:07Z","timestamp":1739984707000},"page":"107664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH"],"prefix":"10.1016","volume":"214","author":[{"given":"Jianhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-7215","authenticated-orcid":false,"given":"Jianyong","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107664_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107664_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107664_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib7","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2025.107664_bib8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib9","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107664_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta Hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107664_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107664_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-beta dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2025.107664_bib16","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/hep.31517","article-title":"17-beta hydroxysteroid dehydrogenase 13 deficiency does not protect mice from obesogenic diet injury","volume":"73","author":"Ma","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107664_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030238","article-title":"CIDE proteins in human health and disease","volume":"8","author":"Slayton","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2025.107664_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/tra.12717","article-title":"CIDE family proteins control lipid homeostasis and the development of metabolic diseases","volume":"21","author":"Chen","year":"2020","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2025.107664_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2008.12.013","article-title":"Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B","volume":"9","author":"Ye","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2025.107664_bib20","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1074\/jbc.M112.434258","article-title":"CideB protein is required for the biogenesis of very low density lipoprotein (VLDL) transport vesicle","volume":"288","author":"Tiwari","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107664_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100156","article-title":"Cideb controls sterol-regulated ER export of SREBP\/SCAP by promoting cargo loading at ER exit sites","volume":"38","author":"Su","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107664_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbalip.2010.01.012","article-title":"Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb","volume":"1801","author":"Li","year":"2010","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2025.107664_bib23","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2337\/db07-0040","article-title":"Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation","volume":"56","author":"Li","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2025.107664_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"Verweij","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107664_bib26","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/liv.15283","article-title":"A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of NAFLD","volume":"42","author":"Mann","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.phrs.2025.107664_bib27","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1038\/ncomms9651","article-title":"Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53","volume":"6","author":"Fei","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107664_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2022.128795","article-title":"Deep learning approach identified a gene signature predictive of the severity of renal damage caused by chronic cadmium accumulation","volume":"433","author":"Feng","year":"2022","journal-title":"J. Hazard Mater."},{"key":"10.1016\/j.phrs.2025.107664_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"10.1016\/j.phrs.2025.107664_bib30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41467-018-03751-6","article-title":"Massive mining of publicly available RNA-seq data from human and mouse","volume":"9","author":"Lachmann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107664_bib31","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2025.107664_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2025.107664_bib33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2025.107664_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2025.107664_bib35","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000466","article-title":"Relationship between hepatic gene expression, intestinal microbiota, and inferred functional metagenomic analysis in NAFLD","volume":"13","author":"Pettinelli","year":"2022","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107664_bib36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/hep.27695","article-title":"Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids","volume":"61","author":"Arendt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107664_bib37","doi-asserted-by":"crossref","first-page":"G462","DOI":"10.1152\/ajpgi.00358.2018","article-title":"Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals","volume":"316","author":"Suppli","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2025.107664_bib38","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/hep.32456","article-title":"Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis","volume":"76","author":"Lei","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2025.107664_bib39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int J. Exp. Pathol."},{"key":"10.1016\/j.phrs.2025.107664_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2025.107664_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107664_bib44","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/ATVBAHA.111.241489","article-title":"CIDE proteins and lipid metabolism","volume":"32","author":"Xu","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107664_bib45","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1074\/jbc.M115.701094","article-title":"Differential roles of cell death-inducing DNA fragmentation factor-alpha-like effector (CIDE) proteins in promoting lipid droplet fusion and growth in subpopulations of hepatocytes","volume":"291","author":"Xu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107664_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107664_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13139-023-00791-9","article-title":"Evaluation of an integrin alpha(v)beta(3) radiotracer, [(18)F]F-FPP-RGD(2), for monitoring pharmacological effects of integrin alpha(v) siRNA in the NASH Liver","volume":"57","author":"Hiroyama","year":"2023","journal-title":"Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.phrs.2025.107664_bib48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib49","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s42003-021-02611-2","article-title":"Targeting integrin alphavbeta3 by a rationally designed protein for chronic liver disease treatment","volume":"4","author":"Turaga","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.phrs.2025.107664_bib50","doi-asserted-by":"crossref","first-page":"G425","DOI":"10.1152\/ajpgi.00050.2011","article-title":"Role of integrins in fibrosing liver diseases","volume":"301","author":"Patsenker","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2025.107664_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107664_bib52","article-title":"Precision medicine and nucleotide-based therapeutics to treat MASH","author":"Caddeo","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib53","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet"},{"key":"10.1016\/j.phrs.2025.107664_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12328-018-0841-9","article-title":"The genetic backgrounds in nonalcoholic fatty liver disease","volume":"11","author":"Seko","year":"2018","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107664_bib55","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41575-024-00915-2","article-title":"Spatial genomics: mapping human steatotic liver disease","volume":"21","author":"Matchett","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11883-023-01158-3","article-title":"Mechanisms behind NAFLD: a system genetics perspective","volume":"25","author":"Pourteymour","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.phrs.2025.107664_bib57","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.phrs.2025.107664_bib58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41580-018-0085-z","article-title":"Dynamics and functions of lipid droplets","volume":"20","author":"Olzmann","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107664_bib59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tcb.2021.01.004","article-title":"Lipid droplet contact sites in health and disease","volume":"31","author":"Herker","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2025.107664_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.devcel.2020.06.026","article-title":"Tether me, tether me not-dynamic organelle contact sites in metabolic rewiring","volume":"54","author":"Bohnert","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.phrs.2025.107664_bib61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41574-023-00845-0","article-title":"Lipid droplet biogenesis and functions in health and disease","volume":"19","author":"Zadoorian","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2025.107664_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Linden","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.107664_bib63","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107664_bib64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2025.107664_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:18:12Z","timestamp":1742437092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":65,"alternative-id":["S1043661825000891"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107664","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107664"}}